Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer.

Fiche publication

Date publication

juin 2024

Journal

Clinical breast cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr CHAIGNEAU Loïc , Dr MENEVEAU Nathalie , Mr MONNIEN Franck , Dr WORONOFF Anne-Sophie , Dr CURTIT Elsa , Dr MANSI Laura , Dr VERNEREY Dewi , Dr SELMANI Zohair , Dr MOLIMARD Chloé , Mr FALCOZ Antoine

Tous les auteurs :
El Kaddissi A, Vernerey D, Falcoz A, Mansi L, Bazan F, Chaigneau L, Dobi E, Goujon M, Meneveau N, Paillard MJ, Selmani Z, Viot J, Molimard C, Monnien F, Woronoff AS, Curtit E, Borg C, Meynard G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38972830

Résumé

Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progression-free survival (PFS) is still an unmet medical need. In this study, we sought to determine potential prognostic criteria for long-term eribulin response in HER2-negative MBC.